Jazz Q1 Earnings, Revenue Decline; Updates Outlook
RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $172
Jazz Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results and Cut Its FY25 Adjusted EPS Guidance. Also, Piper Sandler and Morgan Stanley Lowered Their Respective Price Targets on the Stock.
Express News | Jazz Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results and Cut Its FY25 Adjusted EPS Guidance. Also, Piper Sandler and Morgan Stanley Lowered Their Respective Price Targets on the Stock
Express News | Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $166
A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $166 to $216
